ONS Receives Educational Grants to Fund Conferences

Publication
Article
OncologyONCOLOGY Vol 12 No 6
Volume 12
Issue 6

The Oncology Nursing Society (ONS) recently received grants from Genentech, Inc., to fund two educational projects. A $96,000 grant will fund the ONS National Conference on Cancer Nursing Research to be held in 1999, and a $30,930 grant

The Oncology Nursing Society (ONS) recently received grants from Genentech, Inc., to fund two educational projects. A $96,000 grant will fund the ONS National Conference on Cancer Nursing Research to be held in 1999, and a $30,930 grant will support the Outcomes Research State-of-the-Knowledge Conference to be held later this year.

The goal of the ONS National Conference on Cancer Nursing Research is to bridge the gap between nursing research and practice and create a forum for scholarly exchange. The objectives of the conference are to:

1) discuss state-of-the-art research;

2) examine research outcomes in selected areas of cancer nursing practice;

3) evaluate the application of research findings to cancer nursing practice, education, and policy; and

4) review the application of state-of-the-art research methodologies as they pertain to the study of selected aspects of cancer.

The conference will include plenary and concurrent sessions, a poster session, and roundtable breakfasts so that participants can meet and talk with the speakers.

The Outcomes Research State-of-the-Knowledge Conference will be an invitational meeting based on a competitive review of submitted abstracts. The presentations will focus on identifying and defining nurse-sensitive oncology outcomes, discussing research design and methodologic issues, and addressing future research directions and funding priorities.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
2 experts in this video
Related Content